KALA KALA BIO, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1479419 · Fiscal year ends 12/31
Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY72.9%
TTM EPS YoY196.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-345.3%
ROA-43.2%
ROIC (approx.)-1,688.4%
Asset turnover—
Leverage & solvency
Liabilities / assets14.5%
Debt / equity0.00x
Current ratio6.88x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.97x
Accruals ratio42.0%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $0 | $0 |
| R&D expense | $18.78M | $22.09M |
| SG&A expense | $23.63M | $18.34M |
| Operating income | -$39.16M | -$40.98M |
| Interest expense | $3.28M | $5.78M |
| Income tax | $0 | $0 |
| Net income | -$26.98M | -$38.51M |
| EBITDA | -$38.84M | -$40.72M |
| EPS (basic) | -3.31 | -10.15 |
| EPS (diluted) | -3.31 | -10.15 |
| Weighted avg. shares (diluted) | 8.15M | 3.80M |
| Balance sheet | ||
| Cash & equivalents | $7.56M | $51.18M |
| Current assets | $9.49M | $52.80M |
| PP&E, net | — | $749,000 |
| Total assets | $9.49M | $55.48M |
| Current liabilities | $2.49M | $16.96M |
| Short-term debt | — | $10.34M |
| Long-term debt | — | $20.10M |
| Total debt | — | $30.44M |
| Total liabilities | $2.49M | $43.15M |
| Shareholders' equity | $7.00M | $12.33M |
| Net debt | — | -$20.74M |
| Shares outstanding | 556,995 | 6.09M |
| Cash flow statement | ||
| Operating cash flow | -$31.99M | -$29.38M |
| Investing cash flow | -$15,000 | -$208,000 |
| Financing cash flow | -$11.62M | $29.88M |
| Depreciation & amortization | $317,000 | $259,000 |
| Stock-based compensation | $7.00M | $8.39M |
Free plan shows the latest 2 periods; Pro shows all 11 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.